A Window-of-opportunity Study of Pelareorep in Early Breast Cancer

Stopped Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for the study were met.

Conditions

• Breast Cancer

Interventions

• BIOLOGICAL: Pelareorep
• DRUG: Letrozole
• DRUG: Atezolizumab
• DRUG: Trastuzumab

Sponsor

Oncolytics Biotech

Collaborators

• [object Object]